ZDA
CRL icon

Zweig-DiMenna Associates’s Charles River Laboratories CRL Stock Holding History

Zweig-DiMenna Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,600
Closed -$281K – 143
2017
Q3 		$281K Buy
+2,600
New +$267K 0.03% 149

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Zweig-DiMenna Associates's CRL Position: Q4 2017 in Review

Zweig-DiMenna Associates sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 2,600 shares — an estimated $281K sold.

Zweig-DiMenna Associates first reported a position in CRL in Q3 2017 and held it in 1 quarter. The position peaked at $281K in Q3 2017. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • Zweig-DiMenna Associates reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 2,600 Charles River Laboratories shares in Q4 2017, an estimated $281K.
  • Zweig-DiMenna Associates first reported a position in Charles River Laboratories in Q3 2017 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Charles River Laboratories position peaked at $281K in Q3 2017.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2017, filed 12 Feb 2018.